Paranasal Sinus Cancer Market Scenario
Paranasal sinus cancer market is anticipated to reach USD 2028.53 Million by 2030 at 4.5% CAGR during the forecast period 2022-2030.
Paranasal sinus cancer is one the rare cancer. A paranasal sinus tumor is a cancer that has grown inside sinuses, the open spaces behind the nose.
Numerous factors such as growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, G E Healthcare announced that it has entered into a long term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favourable healthcare expenditures boosts the growth of the market. However, stringent government regulation for product approval and high cost of the treatments may hamper the market growth during the assessment period.
The paranasal sinus cancer market has been segmented into diagnosis, treatment, and end user.
The market, by diagnosis, has been segmented into medical history and physical examination, imaging tests, biopsy, and others. Imaging tests segment is further sub segmented into X-rays, CT (computed tomography) scan, MRI (magnetic resonance imaging) scan, PET (positron emission tomography) scan. Biopsy segment is further sub segmented fine needle aspiration (FNA) biopsy and incisional and excisional biopsies.
The market, by treatment, has been segmented into surgery, radiotherapy and chemotherapy.
The market, by end user, has been segmented into hospital & clinics, cancer treatment & research center, research laboratories, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The paranasal sinus cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European paranasal sinus cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The paranasal sinus cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The paranasal sinus cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Paranasal Sinus Cancer Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)…..
Geographically, the Americas is anticipated to dominate the paranasal sinus cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% people diagnosed with paranasal sinus cancer survive it for five years. Europe is expected to hold the second largest position in the paranasal sinus cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Paranasal Sinus Cancer Market, by Diagnosis
Paranasal Sinus Cancer Market, by Treatment
Paranasal Sinus Cancer Market, by Region
Paranasal Sinus Cancer Market, by Key Players
|Market Size||2030: USD 2028.53 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, and End user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AbbVie, Inc., Pfizer Inc., Eli Lily and Company, Bristol-Myers Squibb Company, Hoffman-La Roche Ltd., Becton, Dickinson and Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Bayer AG|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Paranasal sinus cancer market is projected to grow at a 4.5% CAGR between 2022-2030.
The Americas is expected to lead paranasal sinus cancer market.
Favorable healthcare expenditure and growing geriatric population are the key factors that are driving the paranasal sinus cancer market.
High treatment cost may limit the paranasal sinus cancer market growth.
End users of the paranasal sinus cancer market include research laboratories, hospital and clinics, and cancer treatment and research centre.